Telomir Pharmaceuticals, Inc. (TELO) stock
TELONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.49−0.01 (-1.96%)
Close on Nov 13, 2026Market cap $33.74MP/E –Yield –
Telomir Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Telomir Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.46M, up 74.7% year over year. For fiscal 2025 it was $2.44M, up 9.0% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.44M | +9.0% |
| FY2024 | Dec 31, 2024 | $2.24M | +42.0% |
| FY2023 | Dec 31, 2023 | $1.57M | +88.9% |
| FY2022 | Dec 31, 2022 | $833.21K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $251.89K | -66.8% |
| Q2 FY2026 | Jun 30, 2026 | $444.67K | +938.0% |
| Q1 FY2026 | Mar 31, 2026 | $467.80K | +38.8% |
| Q4 FY2025 | Dec 31, 2025 | $1.30M | +381.7% |
| Q3 FY2025 | Sep 30, 2025 | $759.53K | +21.1% |
| Q2 FY2025 | Jun 30, 2025 | $42.84K | -92.8% |
| Q1 FY2025 | Mar 31, 2025 | $337.00K | -58.1% |
| Q4 FY2024 | Dec 31, 2024 | $269.08K | +32.0% |
| Q3 FY2024 | Sep 30, 2024 | $627.43K | +139.0% |
| Q2 FY2024 | Jun 30, 2024 | $594.80K | -10.9% |
| Q1 FY2024 | Mar 31, 2024 | $804.02K | +82.6% |
| Q4 FY2023 | Dec 31, 2023 | $203.78K | – |
| Q3 FY2023 | Sep 30, 2023 | $262.56K | – |
| Q2 FY2023 | Jun 30, 2023 | $667.63K | – |
| Q1 FY2023 | Mar 31, 2023 | $440.34K | – |
See a number that looks wrong?